The FDA just handed heart failure patients something they’ve been waiting for: a way to skip the hospital for diuretic treatment. On October 7, 2025, the agency approved Lasix ONYU, the first subcutaneous diuretic drug-device combination for home use. No more IV chairs. No more waiting rooms.
Heart failure patients can finally ditch the hospital waiting room for diuretic treatment at home.
This isn’t your typical furosemide. The device delivers 80mg/2.67mL through a small Infusor that patients can use without a healthcare professional hovering over them. The technology combines high-concentration furosemide with something called Captisol to boost solubility and stability. Fancy science aside, it works.
Clinical studies show complete bioavailability at 112% compared to IV infusion. Diuretic response hit 115%, natriuresis reached 117%. The numbers don’t lie—subcutaneous delivery matches IV performance while offering a more controlled, tempered response over time instead of the intense short-term hit from IV bolus.
Heart failure affects 6.7 million Americans, with 1.2 million hospitalizations annually. Those numbers are climbing toward 8.7 million by 2030. Hospital beds are precious real estate, and this technology could free up significant space while reducing the burden on overtaxed healthcare systems. With rural hospital closures increasing nationwide, at-home treatment options become even more critical.
The device features a reusable unit good for 48 treatments plus sterile single-use components. Less waste, lower costs. The two-component design reduces manufacturing complexity, which should translate to fewer adoption barriers across health systems and payers. This marks the seventeenth Captisol-enabled product to receive FDA approval, demonstrating the proven track record of the underlying technology platform. Starting Q4 2025, it’ll be available through major pharmaceutical distributors and retail pharmacies.
But here’s the real question: does this signal the beginning of the end for hospital-based IV diuretic therapy? For stable patients experiencing fluid overload, probably. The biphasic subcutaneous infusion provides controlled drug delivery that mimics IV effectiveness without the hospital infrastructure. The approval follows the recent clearance of bumetanide nasal spray for similar heart failure conditions, indicating FDA’s growing support for at-home diuretic alternatives.
This represents a genuine shift in heart failure management paradigms. Remote monitoring becomes feasible. Home-based care expands. Resource-constrained health systems get breathing room. For selected appropriate patients, clinicians can now prescribe effective diuretic treatment that happens in living rooms instead of hospital rooms.
The technology exists. The approval is official. Now comes the real test—whether this actually reduces those 1.2 million annual hospitalizations.
